Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
"The encouraging efficacy, safety profile and quality of life results from the EMILIA study support our belief that trastuzumab emtansine may have an important role for patients with HER2-positive metastatic breast cancer ... We are working with global regulatory authorities to submit these data as quickly as possible and hope that trastuzumab emtansine will soon be available to patients with this aggressive type of breast cancer."
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Visit our Breast Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Shepherd, Rupert. "Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening." Medical News Today. MediLexicon, Intl., 4 Jun. 2012. Web.
17 Apr. 2014. <http://www.medicalnewstoday.com/articles/246185>
Shepherd, R. (2012, June 4). "Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/246185.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.